Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd banner

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
Watchlist
Price: 3.2 USD -0.31% Market Closed
Market Cap: $4.6B

EV/EBIT

29
Current
11%
Cheaper
vs 3-y average of 32.5

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
29
=
Enterprise Value
$27.1B
/
EBIT
¥926.7m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
29
=
Enterprise Value
$27.1B
/
EBIT
¥926.7m

Valuation Scenarios

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (32.5), the stock would be worth $3.58 (12% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-19%
Maximum Upside
+12%
Average Downside
1%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 29 $3.2
0%
3-Year Average 32.5 $3.58
+12%
5-Year Average 30.4 $3.36
+5%
Industry Average 23.4 $2.59
-19%
Country Average 28.9 $3.19
0%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
$27.1B
/
Jan 2026
¥926.7m
=
29
Current
$27.1B
/
Dec 2026
¥1.7B
=
16.4
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SGX:T14
31.1B USD 29 14.6
US
Eli Lilly and Co
NYSE:LLY
867B USD 30.3 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 21.6 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.4 20.1
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 22.1 28.3
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.8 19.8
US
Merck & Co Inc
NYSE:MRK
283.6B USD 11.8 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.4 10.9
US
Pfizer Inc
NYSE:PFE
151.6B USD 10 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 8.9 16.8

Market Distribution

Lower than 93% of companies in China
Percentile
7th
Based on 5 337 companies
7th percentile
4.8
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
4.6B USD
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

T14 Intrinsic Value
2.22 USD
Overvaluation 31%
Intrinsic Value
Price $3.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett